Introduction {#Sec1}
============

Between 64% and 88% of people with spinal cord damage (SCD) live with chronic pain \[[@CR1]--[@CR4]\]. As pain is associated with reductions in social functioning, community participation, and quality of life, it is consistently listed among the top health-related concerns of individuals living with spinal cord injury \[[@CR5]--[@CR7]\].

People with SCD may have nociceptive and/or neuropathic pain \[[@CR8]\], and both may be difficult to treat \[[@CR9]\]. Data suggest that gabapentinoids \[[@CR10]--[@CR12]\], botulinum toxin A \[[@CR13]\], and antidepressants \[[@CR14], [@CR15]\] may ameliorate pain associated with SCD; weaker evidence supports non-pharmacologic modalities such as acupuncture, massage, and mindfulness exercises \[[@CR16]--[@CR18]\]. Medical cannabis may hold promise as an adjuvant therapy for pain in SCD though it remains relatively understudied with only three small trials having evaluated its efficacy \[[@CR19]--[@CR21]\].

Opioid use in SCD remains controversial \[[@CR22], [@CR23]\]. While recent guidelines for the management of neuropathic pain suggest that tramadol is an effective second-line agent \[[@CR24]\], the authors found only weak evidence supporting use of oxycodone, whose use may be associated with unique side effects and risks. With the pendulum swing from the promotion of opioid use for chronic pain to recommending no new starts and tapering of patients off of opioids, the question arises as to what other medications and treatments clinicians are using for the management of pain in people with SCD and what are clinicians' educational needs regarding pain management. In light of this, the objective of this study was to assess the international spinal cord medicine/rehabilitation community's current utilization of pharmacologic and non-pharmacologic approaches to SCD-related pain. A secondary objective was to determine whether prescribing patterns differ between developed and less developed countries.

Methods {#Sec2}
=======

An online survey was developed and distributed (May through October of 2018) to an international cohort of clinicians who care for individuals with SCD. The survey was developed by three of the authors (MA, PWN, and TB) over several months in an iterative round of revisions. The survey was based on their clinical expertise in the field and awareness of current trends and challenges in treating SCD-associated pain. The survey was distributed by email to the authors' colleagues in the field of spinal cord medicine, to members of the International Spinal Cord Society (ISCOS) via electronic newsletter, and to members of ISCOS-affiliated societies. The survey was available for 6 months prior to analysis.

No identifying details were collected. Consent was implied by participants' completing the survey. No ethics approvals were obtained nor believed necessary for this project.

Descriptive analyses were performed. Responses were analyzed for the entire pool and then separated according to participants' descriptions of their home nations' economies. As far fewer responses were submitted from participants living in countries with developing (*n* = 21) or transitional (*n* = 4) economies than from participants living in countries with developed economies (*n* = 128), they were grouped into the category "developing nation".

Results {#Sec3}
=======

The majority of 153 responses were submitted from Europe and Australia (41.2% and 32.0%, respectively) (Table [1](#Tab1){ref-type="table"}); none were submitted from Africa or South America. Nearly half of subjects (47.1%) were medical doctors, physician assistants, or nurse practitioners and an additional 24.2% were physical or occupational therapists. The remaining responses came from psychologists or counselors (7.0%), nurses (6.4%), and researchers (5.1%). Just over 10% of subjects answered "other," and represented case managers, social workers, educators, and speech and language and recreational therapists. There were no significant differences between the two groups in average years in clinic practice (15.2 developed vs 13.3 developing) or in number of encounters with patients with SCD in the preceding year (176.4 developed vs 94.2 developing).Table 1Demographic and professional dataResponsesDeveloped nationDeveloping nationMedian (IQR; R)Median (IQR; R)Years in practice11.5 (15.7; 54)12.0 (15.0; 34)Patient encounters in past year72.5 (173.7; 1000)50 (70; 390)***n*%*n*%**Continent Africa00 Asia01768.0 Australia4938.20 Europe5542.9832.0 North America2418.70 South America00RoleMedical Doctor/NP/PA5442.92080.0Physical/Occupational therapist3426.528.0Psychologist107.814.0Nursing97.00Researcher75.414.0*NP* nurse practitioner, *PA* physician assistant

A higher percentage of respondents from developing nations were medical doctors, physician assistants, or nurse practitioners (80% vs 43.0%; Table [1](#Tab1){ref-type="table"}). Nearly three quarters (74.5%) of subjects reported that their patients with SCD take opioids for chronic pain (Table [2](#Tab2){ref-type="table"}), though the percentage was higher among respondents from developed nations then among those from developing nations (82.8% vs 32.0%). Fewer participants reported offering their patients cognitive behavioral therapy (CBT) (53.5%), mindfulness exercises (52.2%), implanted stimulators (33.9%), buprenorphine (30.0%), yoga/tai chi (15.6%), or cannabis (13.0%) (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}).Table 2Pharmacological approaches to SCD-related painResponsesTotalDeveloped nationDeveloping nation*n*%*n*%*n*%Confidence in pain diagnosis100%159.8129.3312.075--99%7549.06147.61456.050--74%4630.03829.6832.025--49%85.286.2\<25%95.897.0SCI patients on opioids, *X*^2^ = 43.26, df = 2, *p* = .001Yes11474.510682.8812.0No2214.386.31456.0Do not know1711.11410.9332.0% Patients on opioids0%159.8118.5416.01--20%4428.73325.71144.021--40%1811.71310.1520.041--60%138.5129.314.061--80%231.9232.3081--99%121.3121.50100%10.61070Do not know5737.25341.4416.0Cannabis prescribed at institution, Likelihood ratio = 7.94, df = 2, *p* = .018Yes2013.02015.60No12581.710178.92496.0Do not know85.275.414.0Do you think cannabis should be prescribed? *X*^2^ = 16.87, df = 3, *p* = .007Yes8052.27457.8624.0No2214.31310.1936.0Do not know3724.12821.8936.0% Patients on cannabis0--24%7448.35946.01560.025--49%149.11410.9050--74%31.932.3075--100%31.932.30Do not know5938.54938.21040.0Implanted stimulators offered at facilityYes5233.94535.1728.0No7247.05542.91768.0Do not know2013.01914.814.0% Patients with implanted stimulators0--24%8756.87054.61768.025--49%21.321.5050--74%10.610.7075--100%00Do not know6341.15542.9832.0Buprenorphine prescribed at facility, *X*^2^ = 13.50, df = 2, *p* = .001Yes4630.04031.2624.0No4630.03124.21560.0Do not know6139.85722.5416.0Do you prescribe buprenorphineYes2516.342015.63520.0No11373.869372.662080.0*SCD* spinal cord damage, *SCI* spinal cord injuryTable 3Non-pharmacological approaches to SCD-related painResponsesTotalDeveloped nationDeveloping nation*n*%*n*%*n*%Mindfulness offered at institution Yes8052.26349.21768.0 No4328.13829.6520.0Do not know1711.11410.9312.0% Patients on mindfulness0--24%5435.24635.9832.025--49%2013.01814.28.050--74%149.186.2624.075--100%127.864.6624.0Do not know5334.65039.0312.0CBT offered at facility, *X*^2^ = 7.83, df = 3, *p* = .049Yes8253.57256.21040.0No4529.43225.01352.0Do not know1811.71713.214.0% Patients on CBT0--24%4932.04132.0832.025--49%2214.31914.4312.050--74%95.875.428.075--100%74.532.3416.0Do not know6643.15845.3832.0Acupuncture offered at facility, Likelihood ratio = 9.64, df = 3, *p* = .020Yes3120.23023.414.0No10669.28364.82392.0Do not know127.8118.514.0% Patients on acupuncture0--24%6643.15240.61456.025--49%85.275.414.050--74%53.253.9075--100%000Do not know7448.36450.01040.0Tai chi/yoga offered at facilityYes2415.61814.0624.0No10568.68868.71768.0Do not know1912.41713.228.0% Patients on tai chi/yoga0--24%6743.75341.41456.025--49%85.243.1416.050--74%10.610.7075--100%000Do not know7750.37054.6728.0Want more informationMindfulness3220.92721.0520.0CBT2214.31511.7728.0Opioids and neuropathic74.532.3416.0Efficacy of cannabis4428.74031.2416.0Acupuncture85.275.414.0Tai chi/yoga2013.01914.814.0Buprenorphine95.875.428.0*CBT* cognitive behavioral therapy, *SCD* spinal cord damage

Subjects from developing countries were more likely than those from developed countries to prescribe buprenorphine (20.0% vs 15.6%; *p* = 0.001) and less likely to prescribe medical cannabis (0% vs 15.6%; *p* = 0.001) and acupuncture (4.0% vs 23.4%; *p* = 0.02). Differences in prescription of CBT, mindfulness exercises, tai chi or yoga, and implanted electrical stimulators did not reach significance. While only 13.1% of respondents work at a facility at which medical cannabis is prescribed, 52.3% believe that it ought to be available to patients and just under one third---including 16% from developing nations---expressed interest in learning more about its potential applications. Very few respondents felt they would benefit from additional information about a number of other modalities for treating pain.

Discussion {#Sec4}
==========

To our knowledge, this is the first paper in which an international sample of clinicians caring for people with SCD was polled about utilization of a variety of pharmacologic and non-pharmacologic treatments for pain. The results may prompt further exploration of a variety of aspects of pain management.

Our first finding is that many approaches to pain are being explored and offered by our colleagues in SCD medicine. A plurality of respondents work in facilities in which buprenorphine, mindfulness exercises, electrical stimulation, and CBT are prescribed for SCD-related pain. The variety of available treatments may reflect not only the complexity of pain syndromes suffered by people with SCD but also the difficulty of achieving substantial and sustained relief. It seems that approaches to pain in SCD are often individualized and multimodal.

A second finding is that clinicians working in SCD medicine are not necessarily offering data-driven pain treatments but may, nevertheless, be tailoring their treatments to patients' desires and subjective responses. The CanPain clinical practice guidelines addressing treatment of SCD-related neuropathic pain \[[@CR24]\] suggest that opioid medications (tramadol and oxycodone, specifically) ought to serve as second- and fourth-line therapies, respectively, and that acupuncture, cannabinoids, and electrical stimulation "require further research." While many complementary and alternative therapies may lack sufficient supporting data, Cardenas et al. found that a number of individuals living with SCD report that massage and acupuncture offer substantial and lasting relief from SCD-related pain \[[@CR9]\]. This finding again underscores the difficulty of treating pain in SCD and the potential necessity of employing an "all of the above" strategy in trying to achieve relief.

A third finding is that using medical cannabis for pain relief remains controversial and that facility and governmental policies may be lagging behind clinicians' interest in offering it to patients. Very few respondents work at a facility at which medical cannabis is prescribed but over half believe that it ought to be available to patients and a substantial minority expressed interested in learning more about its potential therapeutic benefits. These data point to a burgeoning interest in medical cannabis among clinicians in SCD medicine, a need for more educational opportunities for clinicians, and to move forward with clinical trials delineating and evaluating its effects.

Finally, it is notable that pain treatments prescribed in developed and developing nations may differ. Respondents from countries with developing economies reported that fewer of their patients are treated with opioids, and significant differences in utilization of other modalities emerged during our analyses. It is not clear whether these differences are driven by educational differences, availability of resources, or clinicians' and patients' cultural beliefs. Our preliminary findings present rich opportunities for further research.

Limitations {#Sec5}
-----------

This paper has several important limitations. First, the survey was available only in English, limiting access to those who are relatively fluent in the language. Second, our distribution strategy likely resulted in selection bias, as clinicians and staff working in academic institutions or who are involved with SCD professional societies were more likely than those with fewer academic and organizational ties to receive the survey. Third, participants were not asked about their use of commonly prescribed and data-supported medications, including gabapentinoids, anti-depressants, and anti-convulsants. Finally, we received no responses from colleagues in Africa or South America and a relative paucity of surveys from individuals living in developing countries. However, this study demonstrates the complexity of managing SCD-associated pain and that most clinicians employ a multi-modal approach. It also raises the possibility that educational differences, resource availability, and cultural beliefs help shape approaches to pain management. Further research addressing these questions would be instructive.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

The authors declare that they have no conflict of interest.
